Loading patent…
AssigneesThe Cleveland Clinic Foundation, Case Western Reserve University
InventorsJohn W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Reganathan
Estimating the term…
The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual. In another embodiment, the invention is directed to methods of inhibiting choroidal neovascularization in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the agent inhibits choroidal neovascularization in the individual.
A method of reducing angiogenesis in an individual in need thereof, comprising administering to the individual an anti-carboxyethylpyrrole (CEP) antibody, wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the antibody reduces angiogenesis in the individual.
A method of reducing choroidal neovascularization (CNV) in an individual in need thereof wherein the CNV is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, comprising administering to the individual an anti-carboxyethylpyrrole (CEP) antibody wherein administration of the antibody reduces the CNV in the individual.
A method of reducing angiogenesis of age-related macular degeneration (AMD) in an individual in need thereof wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, comprising administering to the individual an anti-carboxyethylpyrrole (CEP) antibody, thereby reducing the angiogenesis of the AMD.
Dependencies are inferred from the claim text.